Development of effective ocular preparations of antifungal agents

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 5, 2008, Pages 481-493

  Kaur, Indu Pal ^a   Rana, Cheena ^a   Singh, Harinder ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; AZOPTIC; CONFLU; ECONAZOLE; ELMYCIN; ENDIX G; FLUCOMET; FLUCONAZOLE; FLUTAUR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MICOPTIC; NATAMYCIN; NYSTATIN; OPTICOP; OXICONAZOLE; PHYTORAL; POLYENE; POSACONAZOLE; SERTACONAZOLE; SULCONAZOLE; SYSCAN; TIOCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE; ZOCON;

ABDOMINAL CRAMP; ANEMIA; ANOREXIA; ANTIFUNGAL ACTIVITY; BLURRED VISION; CHEMOSIS; CHILL; CONJUNCTIVAL HYPEREMIA; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRY EYE; ELECTROLYTE DISTURBANCE; EYE DISCOMFORT; EYE IRRITATION; FEVER; FUNGAL EYE INFECTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; INFECTION RISK; KERATOMYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PAPILLEDEMA; REVIEW; TASTE DISORDER; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

ABSORPTION; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EMULSIONS; EYE INFECTIONS, FUNGAL; HUMANS; LIPOSOMES; MICROSPHERES; NANOPARTICLES; OPHTHALMIC SOLUTIONS; SOLUBILITY;

EID: 52449132114     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0031     Document Type: Review

References (106)

1. Whitcher, J.P., Srinivasan M., Upadhyay, M.P., et al. Corneal blindness: A global perspective. Bull World Health Organ. 79:214-221, 2001.
2. Hoflin-Lima, A.L., and Roizenblatt, R. Therapeutic contact lens-related bilateral fungal keratitis. CLAO J. 28:149-150, 2002.
3. Chowdhary, A., and Singh, K. Spectrum of fungal keratitis in North India. Cornea 24:8-15, 2005.
4. Williamson, J., Gordon, A.M., Wood R., et al. Fungal flora of the conjunctival sac in health and disease. Br. J. Ophthalmol. 52:127-137, 1968.
5. Rosa, R.H., Miller, D., Alfonso, E.C., et al. The changing spectrum of fungal keratitis in South Florida. Ophthalmology 101:1005-1012, 1994.
6. Sharma, S., Srinivasan, M., George, C., et al. The current status of Fusarium species in mycotic keratitis in South India. J. Med. Microbiol. 11:140-147, 1993.
7. Dongx, X.L., Shi, W., et al. Penetrating keratoplasty in management of fungal keratitis. Chin. J. Ophthalmol. 35:386-387, 1994.
8. Coster, D. J., Wilhelmus, K., Peacock, J., et al. Suppurative keratitis in London. In: Trevor-Roper, P.D., ed. VIth Congress of the European Society of Ophthalmology. The cornea in health and disease. International Congress and Symposium Series, No. 40. The Royal Society of Medicine, Academic Press, Grune and Stratton, 1981:395-398.
9. Asbell, P., and Stenson, S. Ulcerative keratitis: Survey of 30 years' laboratory experience. Arch. Ophthalmol. 100:77-80, 1982.
10. Rangel, T.R. In: Fungal Keratitis, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution (www.uveitis.org). Vol. 4, No. 3, March, 1999.
11. Sehgal, S.C., Dhawan, S., Chhiber, S., et al. Frequency and significance of fungal isolations from conjunctival sac and their role in ocular infections. Mycopathologia 73:17-19, 1981.
12. Ando, N., and Takatori, K. Fungal flora of the conjunctival sac. Am. J. Ophthalmol. 94:67-74, 1982.
13. Thomas, P.A. Current perspectives on ophthalmic mycoses. Clin. Microbiol. Rev. 16:730-797, 2003.
14. Tanure, M.A., Cohen, E.J., Sudesh, S., et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 19:307-312, 2000.
15. Chander, J., and Sharma, A. Prevalence of fungal corneal ulcers in North India. Infection 22:207-209, 1994.
16. Kunimoto, D.Y., Sharma, S., Garg, P., et al. Corneal ulceration in the elderly in Hyderabad, South India. Br. J. Ophthalmol. 84:54-59, 2000.
17. Sandhu, D.K., Randhwa, I.S., Singh, D. The correlation between environmental and ocular fungi. Ind. J. Ophthalmol. 29:177-182, 1981.
18. WHO. Weekly epidemiology record. 64, 1989.
19. O'Day, D.M. Selection of appropriate antifungal therapy. Cornea 6:238-245, 1987.
20. Le Bourlais C., Acar L., Zia H., et al. Ophthalmic drug delivery systems - recent advances. Prog. Retin. Eye Res. 17:33-58, 1998.
21. Prausnitz, M.R., and Noonan, J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87:1479-1488, 1998.
22. Nagarsenker, M.S., Londhe, V.Y., Nadkarni, G.D., et al. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int. J. Pharm. 190:63-71, 1999.
23. Manzouri, B., Vafidis, G.C., Wyse, R.K., et al. Pharmacotherapy of fungal eye infections. Exp. Opin. Pharmacother. 2:1849-1857, 2001.
24. Online document at: en.wikipedia.org, 2007. Last accessed on August 8, 2007.
25. Online document at: www.rxlist.com, 2007. Last accessed on August 21, 2007.
26. Elephant Formulary, Ophthalmic Products. Online document at: www.elephantcare.org. Last accessed on August 10, 2007.
27. Online document at: www.medclik.com. Last accessed on July 31, 2007.
28. Behrens-Baumann, W. Mycoses of the eye and its adnexa. Dev. Ophthalmol. 32:27-107, 1999.
29. Friedberg, M. L., Pleyer, U., Mondino, B.J., et al. Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps. Ophthalmology 98:725-732, 1991.
30. Online document at: www.drugbank.ca, 2008.
31. O'Brien, T.P. Therapy of ocular fungal infections. Ophthalmol. Clin. North Am. 12:33-50, 1999.
32. Mauger, T.F., and Craig, E.L. In: Mosby, C.V., ed. Havener's Ocular Pharmacology, 6th ed. St. Louis, MO: 1994.
33. O'Day, D.M., and Burd, E.M. Fungal keratitis and conjunctivitis. Mycology. In: Smolin, G., and Thoft, R.A. (ed.). The Cornea: Scientific Foundations and Clinical Practice, 3rd ed. Boston: Little, Brown & Co., 1994:229-239.
34. Mathews, M.S., and Kuriakose, T. Keratitis due to Cephaliophora irregularis Thaxter. J. Med. Vet. Mycol. 33:359-360, 1995.
35. Panda, A., Sharma, N., Das, G., et al. Mycotic keratitis in children: Epidemiologic and microbiologic evaluation. Cornea 16:295-299, 1997.
36. Ritterband, D.C., Seedor, J.A., Shah, M.K., et al. A unique case of Cryptococcus laurentii keratitis spread by a rigid gaspermeable contact lens in a patient with onychomycosis. Cornea 17:115-118, 1998.
37. Rosa, R.H., Miller, D. Jr., Alfonso, E.C., et al. The changing spectrum of fungal keratitis in South Florida. Ophthalmology 101:1005-1013, 1994.
38. Sullivan, L.J., Snibson, G., Joseph, C., et al. Scedosporium prolificans sclerokeratitis. Aust. N. Z. J. Ophthalmol. 22:207-209, 1994.
39. Attapattu, M.C. Acute rhinocerebral mucomycosis caused by Rhizopus arrhizus from Sri Lanka. J. Trop. Med. Hyg. 98:355-358, 1995.
40. Khoo, S.H., Bond, J., Denning, D.W., et al. Administering amphotericin B - a practical approach. J. Antimicrob. Chemother. 33:203-213, 1994.
41. Jacobson, M., Galetta, S.L., Atlas, S.W., et al. Bipolaris-induced orbital cellulitis. J. Clin. Neuroophthalmol. 12:250-256, 1992.
42. Levin, L.A., Avery, R., Shore, J.W., et al. The spectrum of orbital aspergillosis: A clinicopathological review. Surv. Ophthalmol. 41:142-154, 1996.
43. Ribes, J.A., Vanover-Sams, C.L., Baker, D.J., et al. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236-301, 2000.
44. Seiff, S.R., Choo, P.H., Carter, S.R., et al. Role of local amphotericin B therapy for sino-orbital fungal infections. Ophthalmic Plast. Reconstr. Surg. 15:28-31, 1999.
45. O'Day, D.M., Ray, W.A., Head, W.S., et al. Influence of the corneal epithelium on the efficacy of topical antifungal agents. Invest. Ophthalmol. Vis. Sci. 25:855-859, 1984.
46. O'Day, D.M., Head, W.S., Robinson, R.D., et al. Corneal penetration of topical amphotericin B and natamycin. Curr. Eye Res. 5:877-882, 1986.
47. Foster, C.S., Lass, J.H., Moran-Wallace, K., et al. Ocular toxicity of topical antifungal agents. Arch. Ophthalmol. 99:1081-1084, 1981.
48. Wong, T.-Y., Ng, T.-P., Fong, K.-S., et al. Risk factors and clinical outcome between fungal and bacterial keratitis. A comparative study. CLAO J. 23:275-281, 1997.
49. Hirose, H., Terasaki, H., Awaya, S., et al. Treatment of fungal corneal ulcers with amphotericin B ointment. Am. J. Ophthalmol. 124:836-838, 1997.
50. Bernauer, W., Allan, B.D.S., Dart, J.K.G., et al. Successful management of Aspergillus scleritis by medical and surgical treatment. Eye 12:311-316, 1998.
51. Seal, D.V., Bron, J., Hay, J., et al. In: Ocular infection: Investigation and Treatment in Practice. London: Martin Dunitz, 1998:1-275.
52. Kaushik, S., Ram, J., Brar, G.S., et al. Intracameral amphotericin B: Initial experience in severe keratomycosis. Cornea 20:715-719, 2001.
53. Yamaguchi, H., Abe, S., Tokuda, Y., et al. Immunomodulating activity of antifungal drugs. Ann. N. Y. Acad. Sci. 685:447-457, 1993.
54. Johns, K.J., and O'Day, D.M. Pharmacologic management of keratomycoses. Surv. Ophthalmol. 33:178-188, 1988.
55. Foster, C.S. Miconazole therapy for keratomycosis. Am. J. Ophthalmol. 91:622-629, 1981.
56. Fitzsimons, R., and Peters, A.L. Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis. Am. J. Ophthalmol. 101:605-608, 1986.
57. Foster, C.S., and Stefanyszyn, M. Intraocular penetration of miconazole in rabbits. Arch. Ophthalmol. 97:1703-1706, 1979.
58. Hemady, R.K., Chu, W., Foster, C.S., et al. Intraocular penetration of ketoconazole in rabbits. Cornea 11:329-333, 1979.
59. Yoshizumi, M.O., and Banihashemi, A.R. Experimental intravitreal ketoconazole in DMSO. Retina 8:210-215, 1988.
60. Or, M., Akbatur, H., Hasanerisoglu, B., et al. Ketoconazole-induced papilledema. Acta. Ophthalmol. Copenh. 71:270-272, 1993.
61. Ishibashi, Y. Oral ketoconazole therapy for keratomycosis. Am. J. Ophthalmol. 95:342-345, 1983.
62. Ramadan, A.M., Nussenblatt, R.B., de Smet, M.D., et al. Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. Ophthalmology 104:706-711, 1997.
63. Savani, D.V., Perfect, J.R., Cobo, L.M., et al. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother. 31:6-10, 1987.
64. Van Cauteren, H., Heykants, J., de Coster, R., et al. Itraconazole: Pharmacologic studies in animals and humans. Rev. Infect. Dis. 9:(Suppl. 1):S43-S46, 1987.
65. Rajasekaran, J., Thomas, P.A., Kalavathy, C.M., et al. Itraconazole therapy for fungal keratitis. Ind. J. Ophthalmol. 35:157-160, 1987.
66. Thomas, P.A., Abraham, D.J., Kalavathy, C.M., et al. Oral itraconazole therapy for mycotic keratitis. Mycoses 31:271-279, 1988.
67. Thomas, P.A., and Rajasekaran, J. Treatment of Aspergillus keratitis with imidazoles and related compounds. In: Vanden Bossche, H., Mackenzie, D.W.R., and Cauwenbergh, G. (ed.). Aspergillus and aspergillosis. New York: Plenum Press, 1988:267-279.
68. Klippenstein, K., O'Day, D.M., Robinson, R.D., et al. The qualitative evaluation of the pharmacokinetics of subconjunctivally injected antifungal agents in rabbits. Cornea 12:512-516, 1993.
69. Schulman, J.A., Peyman, G.A., Dietlein, J., et al. Ocular toxicity of experimental intravitreal itraconazole. Int. Ophthalmol. 15:21-24, 1991.
70. O'Day, D.M., Foulds, G., Williams, T.E., et al. Ocular uptake of fluconazole after oral administration. Arch. Ophthalmol. 108:1006-1008, 1990.
71. Yee, R.W., Cheng, C.J., Meenakshi, S., et al. Ocular penetration and pharmacokinetics of topical fluconazole. Cornea 16:64-71, 1997.
72. Mochizuki, K., Yamashita, Y., Torisaki, T., et al. Intraocular penetration and effect on the retina of fluconazole. Lens Eye Toxic Res. 9:537-546, 1992.
73. Miyamoto, H., Ogura, Y., Hashizoe, M., et al. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. 16:930-935, 1997.
74. Steinbach, W.J., and Stevens, D.A. Review of newer of antifungal and immunomodulatory strategies for invasion of aspergillosis. CID 37:157-187, 2003.
75. Shah, K.B., Wu, T.G., Wilhelmus, K.R., et al. Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Cornea 22:33-36, 2003.
76. Granados, J.M., Puerto, N., Carrilero, M.J., et al. Efficiency of voriconazole in fungal keratitis caused by Candida albicans. Arch. Soc. Esp. Oftalmol. 79:565-568, 2004.
77. Pleyer, U., Legmann, A., Mondino, B.J., et al. Use of collagen shields containing amphotericin B in the treatment of experimental Candida albicans-induced keratomycosis in rabbits. Am. J. Ophthalmol. 113:303-307, 1992.
78. Schwartz, S.D., Harrison, S.A., Engstrom, R.E. Jr., et al. Collagen shield delivery of amphotericin B. Am. J. Ophthalmol. 109:701-704, 1990.
79. Walker, S., Tailor, S.A.N., Lee, M., et al. Amphotericin B in lipid emulsion: Stability, compatibility, and in vitro antifungal activity. Antimicrob. Agents Chemother. 42:762-766, 1998.
80. Saltoglu, N., Tasova, Y., Zorludemir, S., et al. Rhinocerebralzygomycosis treated with liposomal amphotericin B and surgery. Mycoses 41:45-49, 1998.
81. Strasser, M.D., Kennedy, R.J., Adam, R.D., et al. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch. Intern. Med. 156:337-339, 1996.
82. Moses, A.E., Rahav, G., Barenholz, Y., et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin. Infect. Dis. 26:1430-1433, 1998.
83. Schulman, J.A., Peyman, G., Fiscella, R., et al. Toxicity of intravitreal injection of fluconazole in the rabbit. Can. J. Ophthalmol. 22:304-306, 1987.
84. Segal, B.H., and Walsh, T.J. Current approaches to diagnosis and treatment of invasive aspergillosis. Am. J. Respir. Crit. Care Med. 173:707-717, 2006.
85. Offner, F., Krcmery, V., Boogaerts, M., et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob. Agents Chemother. 48:4808-4812, 2004.
86. Elder, E.J., Evans, J.C., Scherzer, B.D., et al. Preparation, characterization, and scale-up of ketoconazole with enhanced dissolution and bioavailability. Drug Dev. Ind. Pharm. 33:755-765, 2007.
87. Aiache, J.M., Meski, S.E., and Beyssac, E. The formulation of drug for ocular administration. J. Biomat. Appl. 11:329-348, 1997.
88. Burstein, N.L., and Anderson, J.A. Review: Corneal penetration and ocular availability of drugs. J. Ocul. Pharmacol. Ther. 1:309-326, 1985.
89. Green, K., and Downs, S. Ocular penetration of pilocarpine in rabbits. Arch. Ophthalmol. 93:1165-1168, 1975.
90. Kaur, I.P., and Kanwar, M. Ocular preparations: The formulation approach. Drug Dev. Ind. Pharm. 28:473-493, 2002.
91. Keller, N., Moore, D., Carper, D., et al. Increased corneal permeability by the dual effect of the transient tear film acidification and exposure to benzalkonium chloride. Exp. Eye. Res. 30:203-210, 1980.
92. Singh, K., and Mezei, M. Liposomal ophthalmic drug delivery system II. Dihydrostreptomycin. Int. J. Pharm. 19:263-269, 1984.
93. Van Abbe, N.J. Eye irritation: Studies related to responses in man and lab animals. J. Soc. Cosmet. Chem. 24:685-687, 1973.
94. Carafa, M., Santucci, E., and Lucania, G. Lidocaine-loaded nonionic surfactant vesicles: Characterization and in vitro permeation studies. Int. J. Pharm. 231:21-32, 2002.
95. Vyas, S.P., Mysore, N., Jaitley, V., et al. Niosome-based controlled ocular delivery of timolol maleate. Pharmazei 53:466-469, 1998.
96. Manjunath, K., Reddy, J.S., and Venkateswarlu, V. Solid lipid nanoparticles as drug delivery systems. Meth. Find. Exp. Clin. Pharmacol. 27:1-20, 2005.
97. Gasco, M.R., Gallarate, M., Trotta, M., et al. Microemulsions as topical delivery vehicles: Ocular administration of timolol. J. Pharm. Biomed. Anal. 7:433-439, 1989.
98. Gallarate, M., Gasco, M.R., and Trotta, M. Influence of octanoic acid on membrane permeability of timolol from solutions and from microemulsions. Acta. Pharm. Technol. 34:102-105, 1988.
99. Gallarate, M., Gasco, M.R., Trotta, M., et al. Preparation and evaluation in vitro of solutions and O/W microemulsions containing levobunolol as ion pair. Int. J. Pharm. 100:219-225, 1993.
100. Kassem, M.A., Safwat, S.M., Attia, M.A., et al. Influence of the phase volume ratio of multiple emulsions on the ocular activity of prednisolone. STP Pharma. 5:309-315, 1995.
101. Kassem, M.A., Attia, M.A., Safwat, S.M., et al. Preparation and evaluation of hydrocortisone multiple emulsions in rabbit's eye. Pharm. Ind. 56:584-588, 1994.
102. Abdulrazik, M., Behar-Chohen, F., and Benita, S. Drug delivery systems for enhanced ocular absorption. In: Touitou, E., and Barry, B.W. (ed.). Enhancement in Drug Delivery. CRC Press, Taylor & Francis Group, Boca Raton, FL:489-525, 2007.
103. Albertsson, A-C., Carlfors, J., and Carlfors, C. Preparation and characterisation of poly(adipic anhydride) microspheres for ocular drug delivery. J. App. Pol. Sci. 62:695-705, 1998.
104. Parikh, R.H., Parikh, J.R., Dubey, R.R., et al. Poly (D,L- lactide-co-glycolide) microspheres containing 5-fluorouracil: Optimization of process parameters. AAPS Pharm. Sci. Tech. 4:E13, 2003.
105. Hu, T., Le, Q., Wu, Z., et al. Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-β-hydroxybutyrate microspheres. J. Pharm. Bio. Ana. 43:263-269, 2007.
106. Yamaguchi, M., Yasueda, S., Isowaki, A., et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int. J. Pharm. 301:121-128, 2005.